Table 5.
Absolute values, mean (SE) | Least squares mean (SE) absolute or percent change from baseline | Absolute change from baseline relative to placebo (90% CI) | p value* | |||
---|---|---|---|---|---|---|
|
|
|||||
Placebo | Dalcetrapib | Placebo | Dalcetrapib | |||
Most diseased segment mean of maximumTBR†—absolutechange | ||||||
| ||||||
Baseline | 1·81 (0·08) | 2·09 (0·09) | ·· | ·· | ·· | ·· |
Month 3 | 1·86 (0·06) | 1·97 (0·07) | −0·02 (0·06) | −0·11 (0·06) | −0·09 (−0·23 to 0·05) | 0·31 |
Month 6 | 1·82 (0·05) | 1·89 (0·06) | −0·04 (0·06) | −0·19 (0·06) | −0·15 (−0·29 to −0·01 | 0·08 |
| ||||||
Most diseased segment mean of maximumTBR†—percent change
| ||||||
Month 3 | ·· | ·· | −0·5 | −4·4 | −4·0 (−10·4 to 2·9 | 0·33 |
Month 6 | ·· | ·· | −1·1 | −8·4 | −7·3 (−13·5 to − 0·8) | 0·07 |
SE=standard error. TBR=target to background ratio.
p-values (2-sided) are presented for the difference between groups.
n=24 for placebo and n=27 for dalcetrapib at baseline and month 6, and n=24 for placebo and n=26 for dalcetrapib at month 3.